Ocean Biomedical, Inc. shared an update on its broad range of promising programs in malaria, fibrosis, and multiple cancers. On September 14, 2023, Ocean Biomedical will host a Research and Development Day, featuring a live Q&A with its Scientific Co-founders, Dr. Jack A. Elias and Dr. Jonathan Kurtis, who will provide additional insights into their research and development work. The Company's oncology program is advancing several cancer immunotherapy approaches that have the potential to elevate the effectiveness of some of the current cutting-edge cancer treatments, especially focusing on lung cancers and brain cancers, which affect nearly 500,000 patients in the U.S. each year and are leading causes of cancer deaths.

In addition to the multi-pronged cancer program, the Company is advancing a novel malaria vaccine candidate and a companion malaria drug program. The Company is also working to advance a much-needed pulmonary fibrosis treatment candidate to raise the standard of care available to patients with pulmonary fibrosis. Cancer Program.

In addition to advancing immunotherapies for lung, brain, and other cancers, the Ocean Biomedical team is continuing to develop its understanding of the broad anti-tumor mechanisms behind its anti-CHi3L1 discoveries, working to patent additional discoveries, optimizing new treatment candidates, and expanding the potential application of its research and discoveries to more cancers beyond lung cancer and glioblastoma. This work involves simultaneously examining several different antibody approaches, including some that combine with current first-in-class immunotherapy technology to potentially extend the life of those treatments, and some that replace those treatments altogether with next-generation immunotherapy candidates. Updates on Ocean's late-stage preclinical work in oncology include: Recent reresults showing the effectiveness of anti-CHi3L1 in brn cancer, creating a 60% reduction in tutumor growth in human glioblastoma multiforme stem cell model in vivo; -- Recent results showing major lung cancer tumor reduction of 85%-95% in primary lung cancer models of non-small cell lung cancer (NSCLC); -- Experimental results demonstrating Ocean's antibodies inhibit pulmonary metastasis (tumor spread), including malignant melanoma; and -- Extension of patent protections in the U.S. and overseas to cover potential treatments for multiple cancers, including breast cancer, prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, lung cancer, brain cancer, and skin cancer.